Background Since the publication of the British Thoracic Society (BTS) Guideline on the
'Management of opportunistic mycobacterial infections' in 2000, our understanding of the …

Population-based data have documented a continued increase in NTM prevalence since
2000. Annual prevalence in North American and Australia ranges from 3.2–9.8 per 100,000 …

Nontuberculous mycobacteria (NTM) represent over 190 species and subspecies, some of
which can produce disease in humans of all ages and can affect both pulmonary and …

Clinical trials and practice have shown that ethambutol is an important component of the first-
line tuberculosis (TB) regime. This contrasts the drug's rather modest potency and lack of …

During the past decades, a growing interest has been raised in evaluating nontuberculous
mycobacteria (NTM) in patients with noncystic fibrosis bronchiectasis (NCFBE). This paper …

Treatment of Slowly Growing Mycobacteria - Clinics in Chest Medicine Skip to Main Content
Skip to Main Menu Clinics in Chest Medicine Log in Register Log in Subscribe Claim Cart (2 …

SETTING: Tertiary referral center, National Institutes of Health (NIH), USA. OBJECTIVE: To
estimate the mortality rate and its correlates among persons with pulmonary non …

This systematic review and meta-analysis aimed to comprehensively evaluate the factors
associated with mortality and progressive disease in NTM-LD patients. We conducted a …

Background and objective Reliable markers of disease progression or stability to assist in
management decisions are lacking in patients with non‐cystic fibrosis bronchiectasis and …

Bronchiectasis is a chronic respiratory disease characterised by a syndrome of productive
cough and recurrent respiratory infections due to permanent dilatation of the bronchi …